VEGF (vascular endothelial growth factor) and angiogenic signaling represent a novel therapeutic approach for Parkinson's disease targeting the neurovascular unit. The neurovascular coupling between blood vessels and neural circuits is disrupted in PD, contributing to impaired energy metabolism, reduced clearance of alpha-synuclein aggregates, and accelerated dopaminergic neuron death. VEGF signaling promotes angiogenesis, supports neuronal survival through neurotrophic effects, and may restore neurovascular coupling in PD patients.
This category page covers companies developing VEGF receptor agonists, neurotrophic factor programs, and other angiogenic approaches for PD. While this is an emerging field with fewer dedicated programs than anti-alpha-synuclein approaches, several companies are actively developing neurovascular restoration strategies.
###ibiomed
Mechanism: VEGF-mimetic neurotrophic factor (iladRx)
Clinical Stage: Preclinical
Background:ibiomed (formerlyknown as NeuroVast) is developing iladRx, a VEGF-mimetic peptide designed to stimulate angiogenesis and neurotrophic signaling in the brain. The compound is designed to cross the blood-brain barrier and promote the survival of dopaminergic neurons by activating VEGF receptor 2 (VEGFR2) signaling pathways. Preclinical studies in MPTP mouse models of PD have shown improved motor function and reduced dopaminergic neuron loss[@ibio2024].
Key Science:
Mechanism: Neurotrophin-3 (NT-3) / VEGF combination therapy
Clinical Stage: Phase 1 (PD)
Background: Neurounion is developing NU-100, a recombinant neurotrophin-3 fusion protein that also incorporates VEGF receptor binding domains. The approach targets both neurotrophic support and angiogenic restoration simultaneously, addressing two key deficits in PD neurodegeneration. The company reports that NU-100 promotes dopaminergic neuron survival and stimulates angiogenesis in preclinical PD models[@neurounion2024].
Key Science:
###赛诺菲 (Sanofi) — VEGF/VEGFR Research Programs
Mechanism: VEGFR2 modulators (internal research)
Clinical Stage: Discovery
Background: Sanofi has an active research program exploring VEGF receptor modulation for neurodegenerative diseases. While not publicly committed to a PD-specific clinical candidate, internal work has identified VEGFR2 agonists as potential neuroprotective agents for dopaminergic neurons. Sanofi published research demonstrating that VEGFR2 activation protects against 6-OHDA-induced dopaminergic lesioning in animal models[@sanofi2024].
Key Science:
Mechanism: Cerebral blood flow enhancement (CBF restoration)
Clinical Stage: Research
Background: Several academic-industry partnerships are exploring VEGF pathway activation for cerebral blood flow restoration in PD. While no single company dominates this space, the approach is actively researched through NIH grants and academic collaborations. Cerebral hypoperfusion is documented in PD patients, and restoring adequate blood flow through angiogenic approaches may slow disease progression[@nih2024].
Key Science:
| Company | Mechanism | Stage | Notes |
|---|---|---|---|
| Asahi Kasei | VEGF receptor modulator | Preclinical | Japanese company, CNS applications |
| Takeda | Neurovascular restoration | Research | Broad neurodegeneration portfolio |
| AbbVie | VEGF pathway inhibitors | Discovery | Exploring neurotrophic applications |
| Dompé | Neurotrophin analogs | Research | Italian biotech, neurotrophic focus |
| Cellectricon | VEGF screening platform | Research | Contract research for VEGF pathway |
Beyond its well-known role in angiogenesis, VEGF acts as a neurotrophic factor:
PD patients consistently show:
Restoring VEGF signaling in PD could:
VEGF receptor 2 (VEGFR2, KDR/Flk-1) is expressed on dopaminergic neurons of the substantia nigra pars compacta. Activation of VEGFR2 by VEGF promotes:
The coupling between angiogenesis and neuroprotection suggests that VEGF-based approaches may provide dual benefits:
The main challenge with VEGF-based therapies is balancing angiogenic benefits against risks:
| Risk | Mitigation Strategy |
|---|---|
| Tumor angiogenesis | Selective VEGFR2 targeting, CNS-specific delivery |
| Vascular permeability | Using non-permeabilizing VEGF isoforms or mimetic peptides |
| Hemorrhage | Careful dose titration, avoiding existing vascular abnormalities |
| Hypotension | Local delivery or BBB-penetrating small molecules |